CGTX news & sentiment — COGNITION THERAPEUTICS INC

MAR 2·MarketBeatMed

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Rating of "Moderate Buy" from Analysts

Five brokerages have given Cognition Therapeutics (NASDAQ:CGTX) a "Moderate Buy" consensus rating, with an average 1-year price target of $3.33. Institutional ownership has increased significantly to 43.35%, driven by major stake builds and new positions. Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on Alzheimer's, with its lead candidate CT1812 currently in multiple Phase 2 trials.

NOV 17·Benzinga

James M. O'Brien Appointed Chief Financial Officer at Mesoblast - Mesoblast ( NASDAQ:MESO )

NEW YORK, Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Mesoblast Limited ( NASDAQ:MESO, ASX:MSB ) ) , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection with the Company's transition to a fully integrated commercial organization it has appointed ...

NOV 17·GlobeNewswire

James M. O'Brien Appointed Chief Financial Officer at Mesoblast

NEW YORK, Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Mesoblast Limited ( Nasdaq:MESO. ASX:MSB ) , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection with the Company's transition to a fully integrated commercial organization it has appointed ...

$CGTX

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Rating of "Moderate Buy" from Analysts

James M. O'Brien Appointed Chief Financial Officer at Mesoblast - Mesoblast ( NASDAQ:MESO )

James M. O'Brien Appointed Chief Financial Officer at Mesoblast

News on $CGTX